

Attorney Docket No. PC10636A
Application No. 09/833,169

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 14th day of March, 2003.

By

Erica L. Smith
(Signature of person mailing)

Erica L. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Andrew G. Lee, et al.

Examiner: Edward J. Webman

Application No.: 09/833,169

Art Unit: 1617

Filing Date: April 11, 2001

Title: Compositions and Methods for Treating
Female Sexual Dysfunction

Box Non-Fee Amendment
Commissioner for Patents
Washington, D.C. 20231

Sir:

RESPONSE

This is a response to the Official Action dated December 11, 2002.

Remarks

35 U.S.C. § 103(a)

Claims 1, 11, 12 and 40 have been rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over El-Rashidy in view of Halonen et al. Applicants note that claim 10 was not included in this rejection, but was indicated as rejected on the Office Action Summary sheet. Since claim 11 depends on claim 10, which depends on claim 1, applicants believe that claim 10 may have been erroneously omitted from the rejection. However, in view of the remarks below, it is believed that this error is moot.


Applicants respectfully submit that the Halonen et al. patent is not prior art against the present invention, and therefore, this rejection, which is a combination, should be withdrawn. The present application claims priority of U.S. Provisional Patent Application Number 60/266,387, which was filed on April 18, 2000. The Halonen et al. patent was first filed on July 21, 2000, which is after the priority date of the present application. Because the Halonen et al. patent was first filed after the priority date of the present application, the Halonen et al. patent is not prior art against the present application. Applicants respectfully request that the Examiner

reconsider and withdraw the 35 U.S.C. § 103(a) rejection of claims 1, 11, 12, and 40 over El-Rashidy in view of Halonen et al.

Applicants believe that, in view of the remarks made above, this application is in condition for allowance. Reconsideration and allowance of claims 1-5, 10-12 and 40-43 is respectfully requested.

Date: 3/7/2003

By:



Todd M. Crissey
Registration No. 37,807

Pfizer Inc.
Patent Department, MS: 8260-1611
Eastern Point Road
Groton, CT 06340
Phone: (860) 715-4331
Fax: (860) 441-5221